Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
NEW YORK, May 04, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York. Dr. Simpson’s presentation details are as follows:
Panel Presentation:
- Session: Disruptive Injectables & Oncology
- Date and Time: Tuesday, May 8 at 1:45-2:45 p.m. EST
- Location: Track 2 – Room C/D
Corporate Presentation:
- Date and Time: Tuesday, May 8 at 3:25-3:45 p.m. EST
- Location: Room A/B
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: [email protected]
